TABLE 1

Association of candidate SNPs with type 2 diabetes in case and control subjects

Gene (rs number)Type 2 diabetes frequencyRisk alleleHardy-Weinberg equilibrium (P) (control)Allele
Dominant
Recessive
Additive (P)
OR (95% CI)POR (95% CI)POR (95% CI)P
Control
TCF7L2 (rs12255372)TT/TG/GGT0.721
1/33/4532.082 (1.112–3.898)0.0222.059 (1.089–3.893)0.0260.065
0/14/384
TCF7L2 (rs7903146)TT/TC/CCT0.501
2/45/4341.589 (0.978–2.582)0.0611.549 (0.941–2.551)0.0850.132
0/26/372
CDKAL1 (rs7756992)GG/GA/AAG0.053
155/217/1191.307 (1.084–1.577)0.0051.081 (0.796–1.467)0.6181.887 (1.381–2.578)6.8 × 10−52.0 × 10−4
78/217/102
CDKAL1 (rs7754840)CC/CG/GGC0.189
117/225/1491.321 (1.093–1.596)0.0041.209 (0.912–1.604)0.1871.866 (1.316–2.645)4.6 × 10−40.002
57/203/137
HHEX (rs1111875)CC/CT/TTC0.593
44/211/2351.086 (0.885–1.334)0.4301.141 (0.876–1.488)0.3281.018 (0.639–1.620)0.9420.602
35/158/203
HHEX (rs79203837)GG/GA/AAG0.381
17/178/2951.286 (1.015–1.630)0.0371.432 (1.085–1.891)0.0110.920 (0.454–1.866)0.8170.026
15/111/273
IGF2BP2 (rs4402960)TT/TG/GGT0.972
66/196/2311.239 (1.011–1.517)0.0391.175 (0.902–1.530)0.2321.714 (1.103–2.663)0.0160.050
33/163/203
IGF2BP2 (rs1470579)CC/CA/AAC0.940
77/198/2161.334 (1.091–1.630)0.0051.260 (0.967–1.643)0.0871.929 (1.263–2.947)0.0020.007
35/165/198
CDKN2A/B (rs10811661)TT/TC/CCT0.394
189/222/851.227 (1.016–1.482)0.0341.116 (0.792–1.572)0.5311.454 (1.098–1.925)0.0090.031
119/206/75
SLC30A8 (rs13266634)CC/CT/TTC0.395
162/259/721.103 (0.913–1.332)0.3111.439 (1.103–2.044)0.0420.983 (0.742–1.300)0.9020.090
133/188/79
KCNJ11 (rs5219)TT/TC/CCT0.302
83/232/1691.181 (0.974–1.432)0.0901.156 (0.878–1.523)0.3011.436 (0.983–2.099)0.0610.154
50/195/152
  • n = 908. Type 2 diabetes is defined by fasting blood glucose ≥126 mg/dl, or occasional blood glucose ≥200 mg/dl and/or current use of antidiabetic agents. Differences in genotype frequency between diabetic patients and normal control subjects, as well as deviations from the Hardy-Weinberg equilibrium in control subjects, were assessed using the χ2 test.